Cas:95750-97-3 4-(3-chlorophenyl)-1H-pyrazol-5-amine manufacturer & supplier

We serve Chemical Name:4-(3-chlorophenyl)-1H-pyrazol-5-amine CAS:95750-97-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-(3-chlorophenyl)-1H-pyrazol-5-amine

Chemical Name:4-(3-chlorophenyl)-1H-pyrazol-5-amine
CAS.NO:95750-97-3
Synonyms:4,3′-chlorophenyl-5-aminopyrazole
Molecular Formula:C9H8ClN3
Molecular Weight:193.63300
HS Code:2933199090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:423.8ºC at 760mmHg
Density:1.378g/cm3
Index of Refraction:1.67
PSA:54.70000
Exact Mass:193.04100
LogP:2.89350

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4,3′-chlorophenyl-5-aminopyrazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4,3′-chlorophenyl-5-aminopyrazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,3′-chlorophenyl-5-aminopyrazole Use and application,4,3′-chlorophenyl-5-aminopyrazole technical grade,usp/ep/jp grade.


Related News: GEM Bstrong Family Necessities Kits we’re also donated https://www.globalempowermentmission.org/program/family-necessities-kits. Restaurant groups were organized to feed first responders and now we must ensure the survivors have stable and comfortable homes they can start all over in. 16-epi-saikogenin C 3,28-dimethylether manufacturers Lonza is investing CHF 20 million in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investment will allow Lonza to provide a smoother transition from small-scale to large-scale manufacturing for customers. N-hydroxy-3-{1-[2-(2-methoxyphenyl)-ethyl]-2-oxo-2,5-dihydro-1H-pyrrol-3-yl}propionamide suppliers SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. phenyl (2S,3R)-2,3-epoxy-4-methylpentanoate vendor & factory.